One of the limiting factors in the potential use of CGRP agonists therapeutically is that they may cause indications relevant to migraine, flushing, or metabolic changes.1 We therefore examined its effects on activity and core body temperature by radiotelemetry, behavioral responses using a light aversion assay, and signs of flushing by assessing peripheral blood flow. Here, CALCA is linked to migraine disorder.